According to a new report by Patients for Affordable Drugs, Medicare spent an astonishing $46 billion on just two blood thinners between 2015 and 2020.
These are Xarelto by Johnson & Johnson and Eliquis by Bristol Myers Squibb and Pfizer. The list prices of these medications have more than doubled since their introduction to the market, posing a significant burden on the healthcare system and patients.
While list prices are not the final cost of medications after rebates and negotiations between drug manufacturers and payers, they hold significant weight. Particularly concerning is the impact of these rising list prices on Medicare Part D cost-sharing arrangements. Medicare beneficiaries are directly affected, as they have to pay more out of pocket when these list prices increase.
Blood thinners are far from a niche medication. Over 8 million Americans depend on them regularly to manage various conditions like atrial fibrillation, deep vein thrombosis, and pulmonary embolism. Before 2010, warfarin was the go-to option for blood thinning. Though cost-effective, warfarin carries a substantial risk of heavy bleeding, making its use challenging to manage.
However, the landscape began to change in 2011, when Johnson & Johnson introduced Xarelto, followed by Eliquis in 2013. These new entrants promised a better safety profile, reducing the risk of severe bleeding associated with warfarin. However, the cost was significantly higher; while warfarin could be bought for a fraction of the price, these new drugs entered the market with list prices upwards of $200 for a month’s supply.
Over time, the list prices for both Eliquis and Xarelto have surged, and they now stand at over $500 for a month’s supply. While these medications offer advantages in terms of safety and efficacy, the price inflation remains a point of concern. By 2020, Eliquis became Medicare’s top-spending drug, and Xarelto was not far behind as the third-most costly. With nearly 4 million Medicare beneficiaries relying on one of these two drugs, the financial ramifications are hard to ignore.
The rising costs of these blood thinners can have a domino effect on healthcare expenditures and resource allocation. When the healthcare system is burdened with high medication costs, there could be less available for other essential services, diagnostics, and treatments. Moreover, exorbitant out-of-pocket costs could discourage patients from adhering to their medication regimens, risking complications that are costlier to manage in the long term.
The need for affordable yet effective medication is a pressing concern. The significant spending on blood thinners like Eliquis and Xarelto is a stark reminder that balancing drug innovation with affordability remains a critical challenge. As policymakers ponder over healthcare reforms, the findings by Patients for Affordable Drugs offer compelling evidence that change is not just desirable, but urgently needed.
Starting Sept. 1, 2024, a crucial change will occur in the way Medicare deals with high-cost blood thinners like Eliquis and Xarelto. Medicare will pay a negotiated rate for these drugs, a departure from the earlier model, which led to skyrocketing costs. While this is a step in the right direction, for users like myself who rely on Eliquis, the financial burden remains severe. With the existing rates, my insurance and I will still be facing a staggering cost of over $6,000 for my prescription.
While the decision to move to a negotiated rate is commendable, the question remains: is it enough? Again, the list prices for these drugs have more than doubled since their introduction to the market.
Given the scale of the problem, simply introducing a negotiated rate might not be a sufficient solution.
The Centers for Medicare & Medicaid Services (CMS) released in its 2025 Outpatient Prospective Payment System (OPPS) Final Rule a new Conditions of Participation (CoPs)
External audit volume more than doubled in 2024 over 2023 while total at-risk dollars increased fivefold to $11.2 million, impacting healthcare provider organizations’ cash flow
Please log in to your account to comment on this article.
Join Beth Wolf, MD, CPC, CCDS, for an in-depth webcast on the FY2025 spinal fusion MS-DRG updates. Discover key changes in DRG classification, understand impacts on documentation and CMI, and learn strategies to ensure compliance.
Join Angela Comfort, DBA, MBA, RHIA, CDIP, CCS, CCS-P, as she presents effective strategies to strengthen collaboration between CDI, coding, and quality departments in acute care hospitals. Angela will also share guidance on implementing cross-departmental meetings, using shared KPIs, and engaging leadership to foster a culture of collaboration. Attendees will gain actionable tools to optimize documentation accuracy, elevate quality metrics, and drive a unified approach to healthcare goals, ultimately enhancing both patient outcomes and organizational performance.
Optimize your outpatient clinical documentation and gain comprehensive knowledge from foundational practices to advanced technologies, ensuring improved patient care and organizational and financial success. This webcast bundle provides a holistic approach to outpatient CDI, empowering you to implement best practices from the ground up and leverage advanced strategies for superior results. You will gain actionable insights to improve documentation quality, patient care, compliance, and financial outcomes.
Enhancing outpatient clinical documentation is crucial for maintaining accuracy, compliance, and proper reimbursement in today’s complex healthcare environment. This webcast, presented by industry expert Angela Comfort, DBA, RHIA, CDIP, CCS, CCS-P, will provide you with actionable strategies to tackle complex challenges in outpatient documentation. You’ll learn how to craft detailed clinical narratives, utilize advanced EHR features, and implement accurate risk adjustment and HCC coding. The session also covers essential regulatory updates to keep your documentation practices compliant. Join us to gain the tools you need to improve documentation quality, support better patient care, and ensure financial integrity.
Dr. Ronald Hirsch provides critical details on the new Medicare Appeal Process for Status Changes for patients whose status changes during their hospital stay. He also delves into other scenarios of hospital patients receiving custodial care or medically unnecessary services where patient notifications may be needed along with the processes necessary to ensure compliance with state and federal guidance.
Healthcare organizations face complex regulatory requirements under the No Surprises Act and Price Transparency rules. These policies mandate extensive fee disclosures across settings, and confusion is widespread—many hospitals remain unaware they must post every contracted rate. Non-compliance could lead to costly penalties, financial loss, and legal risks. Join David M. Glaser Esq. as he shows you how to navigate these regulations effectively.
Protect your facility from unwanted audits! Join Becky Jacobsen, BSN, RN, MBS, CCS-P, CPC, CPEDC, CBCS, CEMC, and take a deep dive into both the CMS and AMA guidelines for reporting post operative pain blocks. You’ll learn how to determine if the nerve block is separately codable with real life examples for better understanding. Becky will also cover how to evaluate whether documentation supports medical necessity, offer recommendations for stronger documentation practices, and provide guidance on educating providers about documentation requirements. She’ll include a discussion of appropriate modifier and diagnosis coding assignment so that you can be confident that your billing of post operative pain blocks is fully supported and compliant.
During this RACmonitor webcast Dr. Ronald Hirsch spotlights the areas of the OIG’s Work Plan and the findings of their most recent audits that impact utilization review, case management, and audit staff. He also provides his common-sense interpretation of the prevailing regulations related to those target issues. You’ll walk away better equipped with strategies to put in place immediately to reduce your risk of paybacks, increased scrutiny, and criminal penalties.
Copyright © 2024 ICD10monitor. Powered by MedLearn Media.
Prepare for the 2025 CMS IPPS Final Rule with ICD10monitor’s IPPSPalooza! Click HERE to learn more
Get 15% OFF on all educational webcasts at ICD10monitor with code JULYFOURTH24 until July 4, 2024—start learning today!
